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Abstract
Lyme borreliosis, caused by spirochaetes of the Borrelia burgdorferi genospecies complex, is the most commonly reported tick-borne
infection in Europe and North America. The non-speciﬁc nature of many of its clinical manifestations presents a diagnostic challenge
and concise case deﬁnitions are essential for its satisfactory management. Lyme borreliosis is very similar in Europe and North America
but the greater variety of genospecies in Europe leads to some important differences in clinical presentation. These new case deﬁnitions
for European Lyme borreliosis emphasise recognition of clinical manifestations supported by relevant laboratory criteria and may be
used in a clinical setting and also for epidemiological investigations.
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Introduction
Lyme borreliosis (LB), caused by spirochaetes of the Borrelia
burgdorferi sensu lato genospecies complex, is the most com-
monly reported tick-borne infection in Europe and North
America [1] The disease was referred to as Lyme arthritis
following investigation in the town of Old Lyme, Connecti-
cut, USA, in the mid 1970’s into a geographical cluster of
suspected juvenile rheumatoid arthritis cases that were
shown to be associated with tick bites [2]. Further studies
led to isolation of an extracellular spirochaete from the
deer tick, Ixodes scapularis (dammini) [3], subsequently named
Borrelia burgdorferi [4]. Following recognition that this organ-
ism can cause a multi-system disorder affecting a range of tis-
sues including joints, skin, heart, nervous system, and to a
lesser extent some other organs [5], the term Lyme arthritis
was adopted for the arthritic features of the disease and
Lyme disease for the whole spectrum. Many features of the
disease had been known much earlier in Europe under a
variety of names including erythema (chronicum) migrans,
lymphadenosis benigna cutis, acrodermatitis chronica atrophi-
cans, meningopolyneuritis (also known as Garin-Bujadoux-
Bannwarth syndrome) [6]. In Europe the disease is generally
referred to as Lyme borreliosis (LB).
LB in Europe and in North America are very similar in
their main clinical features, but differ in some aspects, evi-
dently due to the greater variety of genospecies that cause
disease in Europe (B. afzelii, B. garinii, B. burgdorferi sensu
stricto, and occasionally other species such as B. spielmanii),
whereas in the US B. burgdorferi sensu stricto is the
only pathogenic genospecies [7,8]. Acrodermatitis chronica
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atrophicans and borrelial lymphocytoma very rarely occur in
the US, but are well-recognised in Europe.
Erythema migrans in Europe, caused by B. afzelii, expands
more slowly and central clearing is more frequent than in the
US where the same manifestation is caused by B. burgdorferi.
However, in American patients systemic symptoms and
seroreactivity are more frequent [9]. Lyme neuroborreliosis
appears to occur in a higher proportion of patients in Europe,
and Lyme arthritis seems to be a more frequent manifestation
in the US. However, data on relative frequency is limited and
bias in reporting systems in both the US and Europe have
made it difﬁcult to reach reliable conclusions [10].
Few countries in Europe have made LB a compulsorily
notiﬁable disease, therefore it is possible to make only
approximate estimates of LB incidence. In most countries
assessment is mainly conducted through diagnostic laborato-
ries reporting on the available details of patients with posi-
tive tests. There are several drawbacks involved in using
such systems for the estimation of LB incidence, including
under-reporting of erythema migrans, varying patterns of test
referrals, varying serodiagnostic criteria and seropositivity
linked to past exposure. Within these limitations it is possi-
ble to gain useful information from individual countries’ sys-
tems through year-to-year comparisons of within-country
data. It is apparent that LB shows a gradient of increasing
incidence from west to east with the highest incidences in
central Europe (e.g. Slovenia, 155/100,000) and the lowest in
the UK (0.7/100,000) and Ireland (0.6/100,000). The real
incidence is most probably higher. A gradient of decreasing
incidence from south to north in Scandinavia and north to
south in Italy, Spain and Greece is also evident [11].
Public perceptions of the disease in Europe have been dis-
torted by the media and by activist groups, with exaggerated
claims of pathogenicity and of difﬁculties of diagnosis and
treatment. While it is true that LB may present diagnostic
and treatment problems, many of the misconceptions result
from misdiagnosis of LB in patients who have other condi-
tions. This can occur because some clinical presentations of
LB are not unique to that infection, and also because inade-
quately standardized and quality-controlled diagnostic meth-
ods are used in some laboratories.
Such problems have necessitated the production of case
deﬁnitions, primarily for epidemiological purposes in the USA
[12] (updated in 2008 [13]) but for clinical management pur-
poses in Europe [14]. Since the publication of the ﬁrst Euro-
pean case deﬁnitions in 1996 the health burden imposed by LB
has increased, partly because of increased incidence in some
regions [15–19]. An additional factor has been the growth of
activist groups promoting nonspeciﬁc case deﬁnitions and
unorthodox, unvalidated diagnostic tests and treatment
regimens that have led to misdiagnoses and adverse events.
This problem has been much more prominent in the USA, but
has increased dramatically in Europe in recent years, causing
harm to patients and creating pressure on both physicians and
politicians. The ﬁrst European case deﬁnitions [14] produced
by the European Union Concerted Action on Lyme Borreliosis
(EUCALB), an EU-funded initiative, were formulated after wide
consultation across Europe. The updated European case deﬁni-
tions presented here have been produced by clinicians on
the EUCALB Advisory Board in order to clarify and improve
the diagnosis and management of LB, and are based on evi-
dence from the peer-reviewed international literature and on
the broad clinical and laboratory experience of the authors.
The literature search strategy included the references in
the ﬁrst European case deﬁnitions [14] and, for more recent
observations and ﬁndings, of searches in Medline, Scopus and
Web of Science for worldwide publications using the follow-
ing keywords ‘Lyme or borreliosis or borrelia or erythema
migrans or neuroborreliosis or borrelia lymphocytoma or
acrodermatitis atrophicans or Lyme carditis or Lyme arthritis
or Lyme encephalopathy or chronic Lyme or post-Lyme’.
Some pre-1996 references that made important contribu-
tions to the literature on the emergence of LB or that con-
cern signiﬁcant diagnostic principles or methodologies have
also been included.
In order to aid reader evaluation of the literature, we
have created a basic categorization system of the publica-
tions cited, as follows:
I. Randomized trials involving adequate numbers of subjects
for statistical analysis.
II. Trials with adequate numbers for statistical analysis, but
without randomization e.g. cohort, case-controlled, mul-
tiple time-series studies.
III. Clear ﬁndings from uncontrolled studies (e.g. case
reports).
IV. Opinions of and descriptive studies by relevant authori-
ties or expert committees (e.g. reviews, guidelines).
These publication categories have been applied to the listed
references.
Note that the above categorization is distinct from the
system used by the Infectious Disease Society of America for
assessing quality of evidence in clinical guidelines [20].
Manifestations of European Lyme
Borreliosis
For a diagnosis of LB to be considered, the patient must
have been exposed to the risk of tick bite. A history of
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documented tick bite is not essential because many tick bites
go unnoticed.
Skin manifestations
Erythema migrans. Erythema migrans (EM; previously referred
to as erythema chronicum migrans) usually occurs several
days to weeks after a tick bite. The lesion starts from a mac-
ule or papule and expands over a period of days to weeks
to form a red or bluish-red patch, with or without central
clearing. The advancing edge is typically distinct and is often
intensely coloured but not markedly elevated [14]. Most EMs
seen by clinicians are more than ﬁve cm in diameter but can
still be diagnosed by experienced clinicians when smaller.
Multiple EMs may also occur. The EM may be accompanied
by fatigue, fever, headache, mild stiff neck, arthralgia and
myalgia, but such symptoms are not indicative of LB if they
occur in the absence of EM [21,22]. EM may be evident for
several months but is self-limiting. However, without appro-
priate treatment other manifestations may follow as a result
of spirochaete dissemination to other tissues. Immunosup-
pression apparently has no statistically signiﬁcant effect on
the clinical presentation, serology or treatment outcome for
EM [23,24]. Erythematous lesions occurring within a few
hours after a tick bite represent hypersensitivity reactions
and do not qualify as EM. Other differential diagnoses may
include insect bite reactions, urticaria, contact eczema, cellu-
litis, folliculitis, erysipelas, tinea corporis, granuloma annulare,
or ﬁxed drug eruption.
The diagnosis of EM is clinical. Serological results in
patients with early lesions are frequently negative but posi-
tive results do not prove EM because background seroposi-
tivity is high in some regions [25,26]. Furthermore, prompt
antibiotic treatment of this manifestation may ablate the anti-
body response [27]. Serology does not contribute signiﬁ-
cantly to a diagnosis of EM. If an atypical manifestation of EM
is suspected clinically, detection of spirochaetes in biopsies
from suspected lesions by culture and/or PCR is helpful in
proving B. burgdorferi s.l. infection.
Borrelial lymphocytoma. Borrelial lymphocytoma (lymphadeno-
sis benigna cutis) is rare. It is a painless bluish-red nodule or
plaque, usually found on the ear lobe, ear helix, nipple or
scrotum and occurs more frequently in children (especially
on the ear) than in adults [14]. In the absence of appropriate
treatment the lesion may persist for months and other mani-
festations of LB may follow [28]. Patients with borrelial
lymphocytoma are usually seropositive at the time of presen-
tation. The small proportion who initially have negative
results usually seroconvert within a short period [29]. His-
tology is required where there is diagnostic uncertainty to
exclude cutaneous lymphoma or other malignancies. Borrelial
lymphocytoma has a typical histological appearance with an
intense polyclonal B-lymphocytic inﬁltrate [30].
Acrodermatitis chronica atrophicans. Acrodermatitis chronica
atrophicans (ACA) is almost exclusively seen in adults, pre-
dominantly women, though ACA-like lesions in children have
been reported occasionally [31]. It is a long-lasting, usually
progressive manifestation of LB, characterised by red or blu-
ish-red lesions, usually on the extensor surfaces of the
extremities. Initially there is a bluish-red discolouration, often
with doughy swelling. Later on skin atrophy becomes more
and more prominent. Fibroid nodules may develop over
bony prominences and sclerodermic changes may develop in
atrophic skin areas [14]. The lesion has a typical histological
appearance with telangiectases, a patchy or band-like lym-
phocytic and plasma cell inﬁltrate, and a greater or lesser
degree of skin atrophy, which, however, is not diagnostic per
se [32]. Involvement of peripheral nerves is not uncommon,
locally at the site of the skin lesion, usually as large-ﬁbre
axonal polyneuropathy with predominantly mild sensory
symptoms [33,34]. Serum IgG antibodies to B. burgdorferi s.l.
are present in high concentrations.
The differential diagnosis of ACA depends on the stage of
the disease. ACA skin lesions on lower extremities are often
falsely interpreted to be a result of vascular insufﬁciency (e.g.
chronic venous insufﬁciency, superﬁcial thrombophlebitis,
hypostatic eczema, arterial obliterative disease), acrocyanosis,
livedo reticularis, lymphedema, a consequence of old age
(‘old skin’) or chilblains. Fibrous nodules are often misinter-
preted as rheumatoid nodules and sometimes as skin
involvement in the course of gout (tophi) or even as
erythema nodosum. It is not unusual for patients with ACA
to consult their doctors because of difﬁculties with footwear
associated with joint deformities, or because of dysesthesias,
hyperesthesias or paresthesias.
Typical examples of EM, borrelial lymphocytoma and ACA
are illustrated in Fig. 1. More illustrations of these conditions
can be found in the previous (1996) publication of European
LB case deﬁnitions [14].
Nervous system manifestations
Lyme neuroborreliosis (LNB) is mainly an acute disease,
which usually develops within a few weeks of infection. In
adults, the disease typically presents as painful meningoradi-
culoneuritis (Garin-Bujadoux-Bannwarth syndrome) and uni-
lateral or bilateral facial palsy. These manifestations may
occur separately or in association [10,11]. Radiculitic
pain caused by LNB can be severe, but usually decreases
rapidly following commencement of appropriate antibiotic
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treatment. Less frequent manifestations include other cranial
neuropathies involving the VI cranial nerve, less frequently
the IV or III and occasionally others. Isolated meningitis in
adults, myelitis, encephalitis, cerebral vasculitis presenting as
stroke are other rare manifestations. In childhood the most
frequent symptoms and signs are headache due to meningitis,
and facial palsy [35]. A variety of other neurological manifes-
tations have been described, mostly as single case reports,
but very few have been proven to be caused by borreliae.
For a reliable diagnosis of LNB, indicative clinical manifesta-
tions must be associated with inﬂammatory cerebrospinal
ﬂuid (CSF) parameters, usually including lymphocytic pleocy-
tosis, although pleocytosis in early LNB is occasionally
absent. IgM and/or IgG antibodies to B. burgdorferi s.l. may be
absent in some patients initially, but speciﬁc intrathecal IgG
production should be detectable in all patients 6–8 weeks
(a) (b)
(c) (d)
(e) (f)
FIG. 1. Skin manifestations of Lyme
borreliosis (pictures by Cortesy of Hasel
Druck und Verlag GmbH, 1090 Vienna,
Austria). (a) Erythema migrans on the
left breast; about 4 weeks after a tick-
bite on this site and 3 weeks after onset
of the lesion. (b) Erythema migrans on
the lower leg; note central clearing. (c)
Borrelial lymphocytoma on the ear lobe.
(d) Borrelial lymphocytoma on the nip-
ple. (e) Acrodermatitis chronica atrophi-
cans on the left leg. (f) Acrodermatitis
chronica atrophicans on the dorsal side
of the hands.
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after onset of symptoms [36]. In most cases acute LNB is a
self-limiting disease, but some features may persist for
months and can result in residual sequelae in a minority of
patients even after antibiotic therapy [37]. Peripheral neuro-
pathy as the sole manifestation of LNB is rarely observed in
Europe other than in patients with ACA [38].
Long-standing (chronic) borrelial infection of the central
nervous system, although very rare, includes long-lasting (at
least six months) manifestations such as chronic meningitis,
encephalomyelitis, and radiculomyelitis [39,40]. The diagnosis
should not be made in the absence of lymphocytic pleocyto-
sis, typically with activated B-lymphocytes and presence of
intrathecally synthesized speciﬁc IgG antibodies in CSF [14].
Further supporting CSF ﬁndings include elevated total pro-
tein and oligoclonal bands.
Musculoskeletal manifestations
Lyme arthritis. Manifestations of Lyme arthritis in Europe, as
in North America, comprise recurrent attacks or long-lasting
objective joint swelling (synovitis), usually in one or a few
large joints most commonly the knee [14]. If left untreated
the condition may persist for months or even years. Arthral-
gia, myalgia or ﬁbromyalgia syndromes alone are not criteria
for musculoskeletal involvement in LB. Spondyloarthritis, for
example sacroiliitis, is not a manifestation of Lyme arthritis.
Likewise, polyarthritis of small joints is very atypical for LB,
and other differential diagnoses, such as rheumatoid arthritis,
must be considered ﬁrst.
There is no single laboratory marker for the diagnosis of
Lyme arthritis. High levels of IgG antibodies to B. burgdorferi
s.l. are found in serum from patients with Lyme arthritis,
but positive serology alone is not sufﬁcient for conﬁrmation,
especially in regions where there is high background sero-
prevalence. In order to substantiate a diagnosis of Lyme
arthritis, alternative explanations for the arthritis should be
excluded, for example osteoarthritis, trauma, spondyloarthri-
tis, crystal-induced arthritis, and septic arthritis. Synovial
ﬂuid analysis is recommended when feasible. Granulocytic
inﬂammation in synovial ﬂuid is a characteristic microscopy
ﬁnding, and direct detection of B. burgdorferi s.l. by culture
or PCR in synovial ﬂuid or membrane is highly supportive of
a diagnosis. Lyme arthritis is sometimes accompanied by
bursitis and/or enthesitis [41], and myositis has also been
proven as a rare manifestation of LB [42]. Lyme arthritis is
one of the rare inﬂammatory joint diseases in which routine
laboratory parameters of inﬂammation, such as C-reactive
protein levels and erythrocyte sedimentation rate, are often
normal. Pronounced elevation of laboratory markers of
inﬂammation in a patient with arthritis argues against Lyme
arthritis.
Cardiac manifestations
Cardiac manifestations in LB appear to be rare. Most fre-
quently they can be observed with or shortly after an EM, or
in association with neurological symptoms or arthritis. Con-
duction abnormalities with varying degrees of atrioventricular
conduction defects are typical manifestations [10,43]. In par-
ticular, Lyme carditis should be suspected in younger individ-
uals showing conduction abnormalities without other
apparent risk factors, and who have a history of recent
exposure to ticks. Other rhythm disturbances, endomyo-
carditis and pericarditis have also been reported [44,45].
Alternative explanations for the cardiac condition presented
must be excluded. Palpitations, bradycardia, or bundle branch
block alone are not sufﬁcient for diagnosis. Antibodies to
B. burgdorferi s.l. should be evident in serum but positive
serology alone is not conﬁrmatory and appropriate clinical
signs must also be taken into account.
Chronic cardiac conditions, such as long-lasting dilated
cardiomyopathy, have occasionally been associated with
borrelial infection but the causal relationship is still unproven
despite direct detection of borreliae from endomyocardial
biopsies in single cases [46].
Ocular manifestations
The recognition of LB as a potential cause of ocular condi-
tions is important for the implementation of appropriate
treatment, although reliable diagnosis is difﬁcult to obtain.
Ophthalmic changes are apparently rare and usually pres-
ent as conjunctivitis in the course of early manifestations of
LB. Uveitis (anterior, intermedia, posterior and panuveitis),
papillitis, keratitis, and episcleritis may occur occasionally
[47,48].
The differential diagnosis of ocular LB is broad and there
is no single laboratory marker for conﬁrmation [49]. Diagno-
sis requires demonstration of speciﬁc serum antibodies and
the exclusion of other causes. Evidence for other manifesta-
tions of LB in recent medical history and pathological ﬁndings
in the CSF may further support the diagnosis. If ocular ﬂuid
is taken, testing for the presence of borrelial DNA by PCR
should be considered.
Objective Long-term Sequelae of LB
Objective long-term sequelae in properly treated patients
are uncommon. Some patients, diagnosed in accordance with
the case deﬁnitions, can take several months to recover fully
following appropriate treatment. Similar slow resolution of
symptoms and signs can occur in patients with many other
systemic infections [50]. Even if some symptoms persist, for
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example after Lyme arthritis, additional long-term manifesta-
tions such as ACA or late LNB apparently do not develop.
Erythema migrans: There is no evidence for objective
long-term sequelae in patients with EM after appropriate
treatment [51].
Lyme neuroborreliosis: Recovery from meningoradiculo-
neuritis and facial palsy may take several weeks to months
and will be complete for most patients, except for a small
number who may suffer from residual paresthesias or facial
paresis. However, in the early weeks of recovery a consider-
able proportion of patients complain about an inability to
work due to neurasthenic symptoms and a reduced toler-
ance to sustained stress. In rare cases, when the diagnosis of
LNB is made late in the course of disease, recovery from
severe neurological symptoms may be incomplete (i.e. pare-
sis, hearing deﬁcits, ataxia, incontinence, cognitive impair-
ment) [39,52].
Acrodermatitis chronica atrophicans: atrophic lesions,
peripheral neuropathy and joint deformities may remain in
patients who sustained severe tissue damage prior to treat-
ment [31].
Lyme arthritis: most patients recover completely but it
may take many months. In a small proportion of treated
patients (less than 10%) Lyme arthritis takes a more pro-
longed course, does not respond to further antibiotic treat-
ment and shows no laboratory evidence (culture or PCR) of
persistent infection. In these cases arthritis is probably driven
by immuno-pathological mechanisms and such patients
should be treated with local or systemic anti-inﬂammatory
agents for symptomatic relief and to hasten resolution of the
inﬂammatory response [53].
Subjective Long-term Sequelae of Lyme
Borreliosis
Some patients report ongoing, recurrent or persistent symp-
toms after appropriate treatment of a proven manifestation
of LB. This problem, described as post-Lyme syndrome (PLS)
[54], is characterized by the persistence of a complex of
symptoms for more than 6 months after treatment. The
symptoms are nonspeciﬁc and include reduced performance,
increased fatigue, irritability, emotional lability, and distur-
bances in sleep, concentration, and memory. Thorough clini-
cal and laboratory assessment of such patients is required to
exclude the possibility of treatment failure or the presence
of a new condition unrelated to previous LB. Various dou-
ble-blind, placebo-controlled studies have so far failed to sup-
port the idea that persistence of borrelial infection is the
cause of such symptoms and have failed to show any sus-
tained beneﬁt from prolonged treatment with antibiotics
[55–60]. PLS is sometimes equated with persistent B. burgdor-
feri s.l. infection and referred to as ‘chronic’ Lyme disease,
but this is a misnomer and PLS does not warrant the use of
expensive and potentially dangerous antibiotics [61]. For
such patients symptomatic treatment is recommended.
Congenital Infection
Despite early suggestions that LB might contribute to unfa-
vourable outcomes in pregnancy [62,63], subsequent studies
have not found such an association and good evidence for
congenital infection is also lacking [64,65].
Laboratory Diagnosis
LB diagnosis should be based primarily on the clinical presen-
tation and an assessment of tick-exposure risk. In most cases
laboratory support is essential because of the nonspeciﬁc
nature of many clinical manifestations.
Culture of spirochaetes from patient material is still the
gold standard for speciﬁcity in the laboratory diagnosis of LB
[66–71]. However, due to the low numbers of viable spiro-
chaetes usually present in patient biopsies and the fastidious
nature of the B. burgdorferi s.l. strains the sensitivity of cul-
ture is highly variable, ranging from less than 1% in Lyme
arthritis to 70% in EM skin lesions [72,73]. Negative results,
therefore, do not exclude active infections. For this reason
and also because successful culture demands expertise and
specialist culture media that is often unavailable in diagnostic
laboratories, culture is not used as ﬁrst line support for clini-
cal diagnosis but may be useful for conﬁrmation and for
uncertain cases.
Serology is usually the ﬁrst and often the only supporting
diagnostic measure to be deployed, because it is relatively
easy to obtain samples, laboratory testing facilities are widely
accessible, and the tests, despite publicised difﬁculties and
controversy, now show acceptable sensitivity and speciﬁcity
[1,71,74]. However, the limitations of antibody tests must be
appreciated. On the one hand the antibody response in early
LB may be weak or absent, especially in EM and early LNB
[75,76]. Furthermore, seroconversion in such patients may
be absent because early antibiotic treatment can ablate anti-
body production [7,27]. On the other hand, a positive spe-
ciﬁc antibody response may persist for months or even years
after successful treatment of the infection, so follow-up of
antibody titres in patients following therapy is not a reliable
approach for monitoring success of treatment [77,78].
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LB serology in much of Europe follows a two-step
approach, involving an initial screening test (usually ELISA),
followed by a western blot for reactive and equivocal sam-
ples [71,73,79–81]. Recent serological research addresses
whether one-step tests, such as ELISAs using the C6 peptide
as antigen, are of sufﬁcient sensitivity and speciﬁcity to
replace the widely used two-step approach. The presence of
several pathogenic genospecies in Europe with variability of
immunodominant antigens, together with the slightly lower
speciﬁcity of the single test approach, may limit successful
application of such single tests [82,83].
Serology is indicated in all cases of clinically suspected LB
except EM, but the less speciﬁc the symptoms, the weaker
the a priori probability of LB, the lower the predictive
value of serological methods [71,76,84]. The probability that
a patient with a positive serological test actually has LB (posi-
tive predictive value) and the probability that a patient with a
negative test does not have the disease (negative predictive
value) depends on the performance characteristics of a given
assay (sensitivity and speciﬁcity) and also on the prevalence
of the disease in the population [72,85,86]. The pre-test
probability of a patient having or not having LB therefore
determines the predictive value of the test result. The signiﬁ-
cance of test results for antibodies to B. burgdorferi s.l. must
therefore be interpreted with caution, especially outside
endemic areas [85].
Technical problems that contribute to false-negative or
false positive results include the adoption of inadequate cut-
off levels, the presence of cross-reacting antibodies, false
positive reactions caused by some autoimmune diseases and
inappropriate interpretation criteria for western blots [66].
Several insufﬁciently evaluated assays for detection of anti-
bodies to B. burgdorferi s.l. are currently on the market and
unfortunately there is no independent, clinically oriented,
pre-market evaluation system for serological assays servicing
the EU as a whole [87].
In patients with LNB, CSF examination is important to
demonstrate typical, though non-speciﬁc, diagnostic clues
such as lymphocytic pleocytosis and inﬂammatory distur-
bances of the blood-brain barrier [1,66,88]. The analysis of
paired serum and CSF samples obtained simultaneously is
key to determining the speciﬁc CSF/serum antibody index
(AI). A positive AI together with typical signs of inﬂammation
in the CSF conﬁrms a clinical diagnosis of LNB [72,88]. Early
on in the course of LNB the speciﬁc intrathecal antibody
response in the CSF may be positive before seroconversion
in the peripheral blood (especially in children), but even in
seronegative patients with early LNB, signs of inﬂammation
are regularly observed in the CSF [35]. It should be empha-
sized, however, that a positive speciﬁc AI may persist for
years after recovery from borrelial CNS infection, whereas
other signs of inﬂammation tend to resolve within a few
months (up to 12) [37,71,89].
Almost all immunocompetent patients with late manifesta-
tions (arthritis, late LNB, ACA) show a positive IgG antibody
response. The diagnosis of so called ‘seronegative chronic
Lyme disease’ in supposed long-standing infections is highly
unsatisfactory, requiring further clinical and laboratory inves-
tigations [1,70,81]. Seronegative late LB, if it occurs at all, is
extremely rare and there have been only two reported
cases of apparently seronegative ACA [90] and one of sero-
negative Lyme arthritis in immunocompetent patients [91].
There are no reliable reports of seronegative late-stage
LNB.
Nucleic acid ampliﬁcation testing using polymerase chain
reaction (PCR) technology greatly assists in the detection
and identiﬁcation of a wide range of fastidious pathogens
and can detect low copy numbers of B. burgdorferi s.l.
[69,75,92,93] However, in European LB the spirochaetemia
is transient and spirochaetes are relatively difﬁcult to sample
from tissues. Furthermore, detection of DNA by conven-
tional PCR cannot unequivocally establish whether infections
are active or not. At present, targets, primers and methods
are not standardized, so test results obtained by different
laboratories may show signiﬁcant variability. Despite these
drawbacks, in the right hands this technique can offer useful
diagnostic support in difﬁcult cases. PCR can detect borreli-
al DNA in over 50% of synovial ﬂuid samples from
untreated patients and even higher levels of detection of
DNA in synovial membranes can be achieved [94,95] In
patients with EM and ACA, borrelial DNA has been
detected in 50–70% of skin biopsies though rarely in their
serum [72,93], and in acute LNB patients borrelial DNA
has been detected in 15–30% of the CSF samples tested
[69,89,93,96] The utility of urine-PCR has been investigated
by several groups, but results are contradictory and urine
PCR is therefore not recommended for routine diagnosis
[69,72,97].
Several diagnostic tests, such as the visual contrast sensi-
tivity test, the lymphocyte transformation test, and CD57+/
CD3- lymphocyte subpopulation typing, cannot be recom-
mended for diagnosis of LB because they lack speciﬁcity
[60,71,98].
Concluding Remarks
Clinical case deﬁnitions for LB in Europe, together with
required supporting laboratory evidence, are summarised in
Table 1.
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Case deﬁnitions are essential for reliable epidemiological
studies and are of great value in clinical management. In clini-
cal studies they can assist in collection and analysis of appro-
priate clinical and laboratory data and facilitate comparison
of ﬁndings from different studies. The case deﬁnitions
described here include basic clinical features and the use of
laboratory data, either as supporting or conﬁrmatory evi-
dence, using methods that are well-characterized in the rou-
tine diagnosis of LB. Serology and culture remain the
cornerstones of laboratory methods for diagnosis of LB.
Although detection of B. burgdorferi s.l. DNA by PCR is
increasingly used in laboratory diagnosis, this method has sig-
niﬁcant limitations and there is no general agreement on the
most appropriate genomic targets for ampliﬁcation and
whether or not positive results are clinically signiﬁcant in
some manifestations of the disease. Other laboratory meth-
ods, reported to be potentially helpful, have not been
included here since protocols remain essentially non-
standardized or their use in a clinical context is not fully
agreed.
These updated case deﬁnitions are designed to assist clini-
cians in the accurate diagnosis of LB in Europe, through
description of the full clinical spectrum of the disease and
recommendations for the use of laboratory support. They
may also be used for epidemiological purposes.
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